Sanofi card trick draws warning

Share this article:
Sanofi card trick draws warning
Sanofi card trick draws warning
A promotional card for Sanofi Aventis's Uroxatral omitted indication and risk information, and also used outdated product labeling, according to a DDMAC warning letter dated October 23 and posted online yesterday.

The front side of the “tent card” reads “Always in the bathroom…especially at night?” and “Relief begins with U,” without providing a full indication for the drug. “These statements misleadingly imply that Uroxatral is approved for…any condition that keeps the patient in the bathroom, such as overactive bladder. Uroxatral is only approved for use in the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH),” the letter said.

Although risk and indication information was printed on the back of the card, DDMAC determined that viewers are unlikely to see it. “The tent card is designed to be adhered to a flat surface (e.g., a pharmacy counter) and as a practical matter, viewers of the front side of the card are unlikely to be able to view the back side of the card once it is stuck in place,” according to the letter.

DDMAC noted a statement on the front of the card directing viewers to safety information on the reverse side, but said the omissions “cannot be corrected” by referencing the back of the card. Information on the back of the card also failed to include an “important warning and precaution regarding Intraoperative Floppy Iris Syndrome (IFIS),” the letter said.

As a result, Sanofi must halt dissemination of the cards, and provide a written response to the letter by November 6, 2009.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.